EU HTA Regulation: Views Wanted On Draft Rules On Joint Scientific Consultations

A newly published draft implementing act sets out the procedural rules for the joint scientific consultations that are foreseen by the EU’s Health Technology Assessment Regulation.

ADVICE
Joint Scientific Consultations will help companies prepare for forthcoming EU-level joint clinical assessments • Source: Shutterstock

Health technology developers will for the next four weeks have a chance to influence the rules governing the joint scientific consultations (JSCs) that will help them prepare for EU-level joint clinical assessments, which go live from January.

HTA Regulation And Joint Scientific Consultations

The 2022 Health Technology Assessment Regulation aims to increase cooperation on HTA across Europe and lays the foundations for EU-level joint clinical assessments. These assessments will be similar to relative effectiveness assessments performed at member state level.

Joint scientific consultations (JSCs), which are also foreseen under the HTA Regulation, allow companies to seek scientific advice from the Member State Coordination Group on HTA during early clinical development.

Industry has expressed concern that the number of JSC slots is inadequate, and that there is a lack of opportunity for companies participate in the JCA scoping process. (Also see "Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines" - Pink Sheet, 19 April, 2024.) 

On 1 October, the European Commission published for consultation its draft implementing act on procedural rules for the JSCs....

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Europe

Plans For EU Biotech Act Shift Up A Gear

 

Companies have until early November to respond to a public consultation from the European Commission on its planned Biotech Act, which it hopes will help unleash the potential of small and midsize enterprises in the bloc.

EU CHMP Opinions And MAA Updates

 

This is an update of recommendations from the European Medicines Agency's Committee for Medicinal Products for Human Use on the authorization of new medicines in the EU, and updates on EU marketing authorization changes recommended by the CHMP.

Vaccine Developers To Benefit From CEPI’s ‘World First’ Adjuvant ‘Matchmaking’ Service

 

Selected vaccine developers will soon be able to use a new adjuvant “matchmaking” initiative that could help create more “effective, potent” vaccines against epidemic and pandemic threats, the Coalition for Epidemic Preparedness Innovations has said.

EMA Tackles Guidance Void As Proposals For External Controls Grow

 

The European Medicines Agency is working on defining when and how external controls can be accepted in clinical research. Among other things, it is looking at the planning, design, conduct, analysis and reporting of studies for which external controls are used.

More from Middle East & Africa

African Medicines Agency Set To Launch With New Leader In April

 

The African Medicines Agency is to appoint a director general and become operational at the end of this month.

New Measures Can Cut Israel’s Drug Approval Time To Just 70 Days

 

Israel has introduced a new framework to expedite the marketing approval of medicines, make the country a more attractive destination for drug registration and help reduce drug prices through market competition.

Landmark Pilot Paves Way for Faster Drug Approvals In Africa

 

In a historic move for Africa, five products have been backed for approval via a pilot that tested a continental listing process.